Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,

#2233 Potential Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumors

Introduction: Prolonged biochemical remission after treatment with steroidogenesis inhibitors has been described in patients with Cushing’s syndrome due to ectopic adrenocorticotropin hormone (ACTH) production. Some studies have suggested antiproliferative and apoptotic effect of ketoconazole in human cancer cells.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Feelders R, Castaño J, Van Dungen R, Dogan-Oruc F,

Keywords: ACTH- and non-ACTH producing NETs, ketoconazole, somatostatin analogs, apoptosis, cytotoxicity,

#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,

#1498 Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-center, Open-label, Dose-escalation Study

Introduction: PAS, a next generation SSA, is investigated to determine the maximum tolerated dose (MTD) in pts with advanced NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Yao J, Chan J, Mita A, Kundu M, Valera S,

Keywords: Pasireotide, MTD,

#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial

Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kulke M, Ruszniewski P, Van Cutsem E, Valle J, De Herder W,

Keywords: everolimus, pNET, pasireotide LAR,